Biochemical measures of ovarian function in female survivors of retinoblastoma treated with intra-arterial melphalan: an initial report. Academic Article uri icon

Overview

abstract

  • Since 2006, ophthalmic artery chemosurgery (OAC) has been used for ocular-sparing treatment of retinoblastoma. Systemic exposure to melphalan is known to cause ovarian dysfunction, but the effect of melphalan-based OAC has not yet been determined. Here, we assess biochemical and symptomatic measures of ovarian function in a cohort of pubertal female survivors of retinoblastoma treated with melphalan-based OAC. These 13 patients all had normal gonadotropins at a median age of 11.1 years, 9.6 years from the completion of therapy. None had symptoms of ovarian dysfunction. This study provides initial evidence that ovarian function remains intact after melphalan-based OAC.

publication date

  • December 1, 2022

Research

keywords

  • Retinal Neoplasms
  • Retinoblastoma

Identity

Scopus Document Identifier

  • 85147048328

Digital Object Identifier (DOI)

  • 10.1080/13816810.2022.2132516

PubMed ID

  • 36695494

Additional Document Info

volume

  • 43

issue

  • 6